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BACKGROUND/OBJECTIVE: Intertrochanteric hip fractures are amongst the most common and 
most expensive diagnoses in the Medicare population. Opioids have long been the mainstay of 
treatment however, with their high risk of adverse events, especially in the elderly, there is an effort 
to find non-narcotic modalities of pain management. Liposomal bupivacaine (LB) is a novel 
preparation of a commonly used analgesic agent that when used intra-operatively decreases narcotic 
requirements, decreases hospital length of stay and increases likelihood of discharge to home. The 
objective of this study is to determine whether there is an economic benefit to utilizing intraoperative 
liposomal bupivacaine in patients with fragility intertrochanteric femur fractures in comparison to a group 
of patients who did not receive liposomal bupivacaine. 
DESIGN/METHODS: Retrospective observational study at two academic medical centers. Fifty-six 
patients with intertrochanteric hip fractures treated with cephalomedullary nail implant who received 
standard hip fracture pain management protocol were compared to a cohort of forty-six patients with 
intertrochanteric hip fractures who received additional intraoperative injections of liposomal 
bupivacaine. All other standard of care was identical. Standard of care was set at P < 0.05.  
 
RESULTS: Although the length of hospital stay was similar between the two groups (3.2 days vs 3.8 
days, p =0.08), patients receiving intraoperative liposomal bupivacaine had lower likelihood of 
discharge to skilled nursing facility (84.8% vs 96.4%, p = 0.002) and a longer operative time (73.4 
min vs 67.2 min, p =0.004). A cost benefit analysis indicated that for an investment of $320 in the 
administration of LB, there was a relative savings of $528.90 compared to the control group. The 
benefit:cost ratio was 1.65, indicating a $1.65 benefit for each $1 investing in liposomal bupivacaine.   
 
CONCLUSIONS: Despite an increased initial cost, intra-operative use of liposomal bupivacaine was 
found to be a cost-effective intervention due to a higher likelihood of discharge to home during the 
postsurgical management of patients with intertrochanteric hip fractures. 
 
